# Vera Therapeutics, Inc.: overview

VERA · Nasdaq · CIK 1831828 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vera.md) · [Financials](/companies/vera/financials.md) · [Filings](/companies/vera/filings.md) · [Insiders](/companies/vera/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.85)](/filings/0001193125-25-266881.md) | not reported | [(0.81)](/filings/0001193125-26-212143.md) | [(1.20)](/filings/0001193125-26-342380.md) | [(1.26)](/filings/0001193125-25-266881.md) | not reported | [(1.69)](/filings/0001193125-26-212143.md) | [(1.52)](/filings/0001193125-26-342380.md) |
| Free cash flow | $m | [(37.1) d](/filings/0001193125-25-266881.md) | [(39.8) d](/filings/0001193125-26-077442.md) | [(54.6)](/filings/0001193125-26-212143.md) | [(55.0) d](/filings/0001193125-26-342380.md) | [(62.0) d](/filings/0001193125-25-266881.md) | [(70.1) d](/filings/0001193125-26-077442.md) | [(107)](/filings/0001193125-26-212143.md) | [(100) d](/filings/0001193125-26-342380.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.43)](/filings/0000950170-23-010288.md) | [(3.35)](/filings/0000950170-24-036729.md) | [(2.25)](/filings/0001193125-26-077442.md) | [(2.75)](/filings/0001193125-26-077442.md) | [(4.66)](/filings/0001193125-26-077442.md) |
| Free cash flow | $m | [(23.7)](/filings/0000950170-23-010288.md) | [(67.7)](/filings/0000950170-24-036729.md) | [(92.2)](/filings/0001193125-26-077442.md) | [(136)](/filings/0001193125-26-077442.md) | [(242)](/filings/0001193125-26-077442.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vera/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $246.6m | 5,747,760 |  | Added +659,658 |
| [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $245.6m | 5,723,888 |  | Reduced −165,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $178.0m | 4,148,786 |  | Added +785,148 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $171.6m | 4,000,000 |  | Reduced −106,067 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $168.1m | 3,916,400 |  | Added +194,300 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $124.0m | 2,890,059 |  | Reduced −508,165 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $120.1m | 2,799,459 |  | Added +2,430,699 |
| [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $119.9m | 2,793,987 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $119.0m | 2,774,070 |  | Added +97,648 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $118.2m | 2,755,413 |  | Added +71,806 |

## Recent filings

[All 466 filings](/companies/vera/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-15 | 06:45 ET | [8-K](/filings/0001193125-26-391280.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-391280 |
| 2026-08-10 | 16:10 ET | [10-Q](/filings/0001193125-26-342380.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342380 |
| 2026-08-10 | 16:05 ET | [8-K](/filings/0001193125-26-342335.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342335 |
| 2026-07-09 | 08:00 ET | [8-K](/filings/0001193125-26-299165.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-299165 |
| 2026-07-07 | 12:45 ET | [8-K](/filings/0001193125-26-297211.md) | 8.01 Other events | 0001193125-26-297211 |
| 2026-06-02 | 07:05 ET | [8-K](/filings/0001193125-26-252475.md) | 8.01 Other events | 0001193125-26-252475 |
| 2026-05-26 | 16:54 ET | [8-K](/filings/0001193125-26-239559.md) | 5.07 Shareholder vote results | 0001193125-26-239559 |
| 2026-05-07 | 16:33 ET | [10-Q](/filings/0001193125-26-212143.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212143 |
| 2026-05-07 | 07:30 ET | [8-K](/filings/0001193125-26-210351.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210351 |
| 2026-04-09 | 16:05 ET | [DEF 14A](/filings/0001140361-26-014002.md) | Proxy statement, period 2026-05-21 | 0001140361-26-014002 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-077442.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1831828
- Tickers: VERA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.